Cybrexa Unveils Promising Preclinical Data on Tumor-Selective PDCs at ESMO 2025
Cybrexa Therapeutics presented preclinical data at the ESMO Targeted Anticancer Therapies Congress 2025, showcasing their alphalex™ peptide-drug conjugates (PDCs)....
Reunion Neuroscience Raises Post Pardum Depression at MMH Forum
Reunion Neuroscience is participating in the 2025 Maternal Mental Health (MMH) FORUM to discuss RE104, its lead product candidate...
Onward Medical Advances Parkinson’s Pipeline with DoD, MJFF Support
ONWARD Medical received two grants to support early clinical feasibility studies of its ONWARD ARC-IM System for Parkinson’s disease....
Adverum Launches Phase 3 Study of Ixo-Vec for Wet AMD
Adverum Biotechnologies has launched the ARTEMIS Phase 3 study, a pivotal trial evaluating the efficacy and safety of a...
Pliant Therapeutics Announces Update on Phase 2b/3 Idiopathic Pulmonary Fibrosis Trial
Pliant Therapeutics halted its Phase 2b BEACON-IPF trial of bexotegrast for idiopathic pulmonary fibrosis (IPF) due to an imbalance...
Celldex’s Cdx-622 Shows Promise in Preclinical Inflammatory Disease Study
Celldex Therapeutics announced positive preclinical data for CDX-622, a bispecific antibody targeting thymic stromal lymphopoietin (TSLP) and stem cell...
NKgen Biotech Administers First Troculeucel Dose to Stroke Patient
NKGen Biotech administered its expanded autologous NK cell therapy, troculeucel, to a stroke patient under an FDA-cleared compassionate use...
Oryzon Defines Phase III Trial Endpoints for Agitation & Aggression in BPD
Oryzon Genomics has established primary and key secondary endpoints for its Phase III clinical trial of vafidemstat for Borderline...
Spectral Medical’s Tigris Trial Update
Spectral Medical Inc. (TSX: EDT) announced an update on its Tigris Phase 3 trial, which is evaluating Polymyxin B...
MBX Biosciences Completes Avail™ Phase 2 Trial Enrollment
MBX Biosciences completed enrollment in its Phase 2 Avail™ trial of canvuparatide, a parathyroid hormone (PTH) prodrug for chronic...